Stead, L.F. orcid.org/0000-0002-9550-4150 (2022) Treating glioblastoma often makes a MES. Nature Cancer, 3 (12). pp. 1446-1448. ISSN 2662-1347
Abstract
Glioblastoma (GBM) brain tumor cells exhibit pronounced phenotypic plasticity, but exactly how this enables GBMs to inevitably resist standard treatment is not known. A new study uses multilevel molecular profling of pre- and post-treatment human GBMs to shed light on treatment response with single-cell and spatial resolution.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use (https://www.springernature.com/gp/open-research/policies/accepted-manuscript-terms), but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1038/s43018-022-00471-1 |
Dates: |
|
Institution: | The University of Leeds |
Academic Units: | The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Medical Research (LIMR) > Division of Molecular Medicine |
Depositing User: | Symplectic Publications |
Date Deposited: | 04 Jan 2024 17:05 |
Last Modified: | 04 Jan 2024 17:06 |
Published Version: | https://www.nature.com/articles/s43018-022-00471-1 |
Status: | Published |
Publisher: | Springer |
Identification Number: | 10.1038/s43018-022-00471-1 |
Related URLs: | |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:207152 |